Objective There have been few studies on cyclosporine (CsA) monotherapy in adult minimal change nephrotic syndrome (MCNS). To delineate CsA therapy as new treatment options for MCNS, we conducted a prospective single-center study.
Introduction
Corticosteroid therapy remains the principal treatment for minimal change nephrotic syndrome (MCNS) but has not been thought to be an ideal treatment for MCNS in adults because of the potential risk of several serious side effects or frequent cosmetic problems. Also, for adult MCNS patients, the response to corticosteroid appears to be lower and slower to develop than in children (1) . In this respect, previous studies suggested PMT-based treatment, combined with corticosteroid, and these protocols rapidly induced remission in steroid-sensitive or steroid-resistant nephrotic syndrome (2, 3) . On the other hand, the action of Cyclosporine (CsA) as an anti-T-cell agent, seemed more rational than corticosteroid to use for postulated T-cell abnormalities in the clinical setting for MCNS. We reported the successful initial remission-inducing effect of low-dose CsA alone in cases of first-attack or the occasional relapse of MCNS (4) . In general, however, CsA has not been used as the first drug of choice in MCNS because of its potential nephrotoxicity (5) . However, the nephrotoxicity is believed to be dose dependent, and to be more severe in focal segmental glomerular sclerosis and in steroid-resistant than in steroid-dependent nephrotic syndrome (6) . In the published reports, tapering or withdrawing of CsA resulted in relapses of the nephrotic syndrome. Concerning this point, it was postulated that the long-term use and slow tapering of CsA might resolve the problem of its dependency (7) .
To determine the actual benefits and risk of CsA monotherapy, we conducted a prospective single-center study. We studied the clinical efficacy of CsA alone at a lower dose for a longer term and with slower tapering, than the dose, term, and tapering period previously reported, and also studied the additive values of CsA combined with intravenous pulse methylprednisolone therapy as a new treatment option.
Materials and Methods

Patients
We prospectively assessed the long-term efficacy of CsA treatment. Fifty Japanese adult-onset MCNS (16 to 82 years old) were admitted to the Department of Nephrology of Tokyo Medical University from 1995 to 2000. Two of 50 patients were in spontaneous remission. The remaining 48 patients were treated by our treatment protocols. However, 2 with advanced malignancy, 3 aged over 69 and 7 with inadequate follow-up were excluded from the study. Thus, the present study consisted of 36 patients (34.8±16.4 year old; 19 males/17 females) with 26 first attack and 10 occasional relapse of MCNS. Renal biopsy had been performed in all the patients on admission. MCNS was diagnosed by light microscopic and immunofluoresence studies, with or without electron microscopy, using standard methods. At entry into the study none of the patients were being treated with corticosteroids or cytotoxic agents. All patients were fully informed of the risks and benefits of each treatment and provided consent.
Treatment protocol
The 36 patients were treated with the three different regimens of our treatment protocol. CsA, in the form of Sandimmun capsules (Novartis, East Hanover, NJ, USA), without oral corticosteroid was given orally in two different regimens: in 12 patients, CsA alone was given orally at 2-3 mg/kg/d, in another 12 patients, CsA after intravenous pulse methyprednisolone therapy (PMT, 1,000 mg within 2 hours ×3 consecutive days) was given orally at 2-3 mg/kg/d (CsA/PMT). CsA was administered for 12 months, tapered by 25 mg every 2 months, and then stopped. Twelve patients received oral prednisolone (PSL) alone twice daily as the initial treatment in a total dose of 40-60 mg/day. Maximal dose was maintained for 4-6 weeks, then the daily dose was tapered slowly, and stopped at 12 to 18 months after initial treatment.
Whole blood CsA trough levels were monitored every 4 weeks initially with a specific monoclonal RIA method, and subsequently at 8-week intervals. The lower limits of blood trough levels were not adjusted, but the upper limits of blood trough levels were targeted on maintaining levels below 150 ng/ml. In cases of no response within the 4-week period, LDL apheresis (2 times per week, for 3 consecutive weeks) or intravenous PMT (1,000 mg ×3 consecutive days) was performed.
General management
All patients were on a low-sodium diet (5 g/day), and marked edematous patients were given oral or intravenous furosemide. None of patients received intravenous albumin. We tried to reduce cholesterol with doses of up to 10 mg of simvastatin given simultaneously with CsA in the patients with severe hypercholesterolemia.
Definitions
Nephrotic syndrome was diagnosed by the presence of edema, proteinuria in excess of 3.5 g/d, and serum albumin of less than 3.0 g/dl. The response of nephrotic syndrome was categorized as either complete remission or no response. CR was defined when proteinuria dropped to under 150 mg/ day for 3 consecutive days. No response was defined by proteinuria of more than 3.5 g/day at 4 weeks after initial treatment. Relapse of nephrotic syndrome was suggested by appearance of proteinuria lasting more than 1 week, and was defined by proteinuria in excess of 3.5 g/day.
Follow up
After discharge, all 36 patients were observed as outpatients in our institution. The mean follow-up of 36 patients was 38.9±16.3 months (from 12 to 72 months) after treatment. In the case of relapse, the initial protocol was repeated. A CsA-dependent or steroid-dependent course was defined by the appearance of either two consecutive relapses when CsA or steroid was tapered or stopped, or relapses within the first month after treatment was halted. When patients had CsA-or steroid-dependency, they were also given low-dose PSL or low-dose CsA, respectively. The time of starting combination therapy was taken as the endpoint of the followup period.
Blood pressure, body weight, urinary protein, serum creatinine level, and 24 hours creatinine clearance were checked regularly. Symptoms, especially those of CsA or corticosteroid toxicities were observed carefully.
Assessment of clinical efficacy
The induction rate of CR, the number of days until CR, and hospitalization periods were evaluated as short-term effects. Long-term effects examined were the rate of sustained remission (defined as having no relapse) after the initial treatment and these were compared among the 3 treatment arms. The evaluation of adverse effect of each treatment consisted of renal function, blood pressure, the changes in body weight, or typical symptoms of CsA or corticosterid toxities. 
Statistical analysis
Statistics were analyzed with Statview 5.0 software. Values were expressed as means±SD. Dichotomous and polytomous data were analyzed by the chi-square test and Fisher's extract test. Unpaired t-test was used for unpaired comparison and paired t-test was used for paired comparison between two groups. ANOVA was used for the comparison among 3 groups, and repeated measures ANOVA was also used for evaluation of serial changes of parameters. Cumulative incidence of developing events from the initial treatment were estimated by the Kaplan-Meier method and compared by the log-rank test. A value of p<0.05 was considered to indicate a statistically significant difference.
Results
Clinical characteristics of the patients
No significant differences among the 3 groups were found in clinical characteristics (age, gender, status, urinary protein, serum albumin, and serum cholesterol) of the nephrotic syndrome before treatment as shown in Table 1 .
Short-term response
The mean maintenance dosage of CsA was the same in the CsA alone and CsA/PMT groups (2.76±0.37 mg/kg/d vs. 2.71±0.41, NS). Mean blood trough levels of maintenance CsA were equally relatively low in the 2 CsA groups (75.5± 36.8 ng/ml vs. 74.4±29.4, NS). The induction rate of CR was 75% (9/12) in the CsA alone group, 100% in the CsA/PMT group, and 92% (11/12) in the PSL alone group. The 3 patients (patients 8, 9, 11) who failed to respond to CsA alone had severe hypercholesterolemia (Table 1) . Two (patients 9, 11) of the 3 patients responded to LDL apheresis and the other (patient 8) to PMT. Mean time to CR was short in the CsA/PMT group and long in the CsA alone group (40.9±35.5 days with CsA alone; 11.0±5.6 with CsA/PMT; 21.5±15.8 in PSL alone, p=0.0018) ( Table 1 ). The cumulative rates of CR were significantly different among the 3 treatment arms (p<0.0001) (Fig. 1) . Periods of hospitalization were least in the CsA/PMT group, and maximum in PSL (39.5±17.5 days with CsA alone; 23.7±8.9 with CsA/PMT; 57.5±24.3 with PSL alone, p=0.0007).
Long-term response
The observation periods were the same among the 3 different treatment arms (43.0±18.7 months in CsA alone; 37.8±10.5 in CsA/PMT; 36.2±18.8 in PSL alone, NS). Relapses (patient 22 only, in the CsA/PMT group) among the 3 treatment arms were infrequent when a maintenance dose of CsA or PSL was continued. Relapses during or after the first course of each treatment were seen in 7 of 12 in the CsA alone group, 4 of 12 in CsA/PMT, or 8 of 12 in PSL alone, but were not statistically different (p=0.3768) ( Table   1 ). Six of the 7 patients with CsA alone relapsed during the tapering period and 1 patient (patient 4) relapsed at 3 months after withdrawal of CsA (Table 1) . Three (patients 14, 16, 17) with CsA/PMT relapsed during the tapering period ( Table 1 ). The cumulative rates of sustained remission after the first course of treatment among the 3 treatment arms were not statistically different (p=0.2206). Table 2 showed treatment at last observation. Frequency of the medicationfree patients was highest in the CsA/PMT group; 8 of 12 patients with the CsA/PMT group were in remission without medicine. However, the frequency among the 3 treatment groups was statistically the same.
Adverse reactions
In serial changes of serum creatinine and blood pressure during each treatment period, there were no significant differences among the 3 different treatment groups by repeatedly measured ANOVA. The values of creatinine clearance on final observation were the same as pretreatment baseline levels in all groups (105.5 to 105.4 ml/min with CsA alone, NS; 107.7 to 109.8 ml/min with CsA/PMT, NS; 90.6 to 96.1 ml/min in PSL, NS). One patient with CsA alone developed new-onset hypertension and mild gingival hyperplasia. No patient developed renal dysfunction. Lanugo developed in 4 patients, but they did not develop hirsutism. The lanugo disappeared after tapering or stopping CsA. No adverse effect associated with PMT was observed. Three patients with PSL alone experienced major side effects of corticosteroid: gastric ulcer bleeding, diabetes mellitus with euglycemic agents, aseptic necrosis of the femoral head. Most patients with PSL complained of cosmetic problems: 7 with moon face, 3 with acne, 2 with hirsutism, 2 with obesity, and 1 with hair loss. The changes of body weight from remission to final observation was much in PSL alone, but not statistically different (-2.05±3.33 with CsA alone vs. +0.25±2.86 with CsA/PMT vs. +2.56±4.32 with PSL alone, p=0.2278).
Six patients who experienced relapse on tapering of CsA received repeat biopsy at 24 to 36 months after initial treatment. No patient had characteristics of CsA nephrotoxicity such as tubular atrophy accompanying focal stripped interstitial fibrosis or arteriopathy. The repeat biopsy specimen of a patient with CsA dependency was consistent with a cellular variant of focal segmental glomerulopathy with moderate interstitial fibrosis, but was not typical of chronic CsA nephrotoxicity.
Discussion
This article reports our single-institute experience with long-term low-dose treatment of CsA with slow tapering in Japanese adults with MCNS. Ideal treatment of nephrotic syndrome comprises rapid induction, longer term sustained remission and few adverse reactions. Among our three regimens, CsA/PMT therapy as new treatment option may be the nearest to the ideal treatment presently available for MCNS.
Induction of CR
In several previous studies, PMT-based treatment combined with corticosteroid protocols rapidly induced remission in steroid-sensitive or steroid-resistant nephrotic syndrome (2, 3). However, PMT without corticosterids was significantly less effective than conventional regimens and failed to induce remission within 2 weeks of treatment in 6 of 9 patients for the first episode of MCNS (8) . Otherwise the CsA/PMT therapy induced a CR in a mean time of 11 days, therefore, the successful results of CsA/PMT may be achieved by combined effects of CsA with PMT.
CsA alone could successfully induce CR in 9 of 12 cases although the times required to achieve CR in the CsA alone group was the longest among the 3 treatment arms. The high 25  26  27  28  29  30  31  32  33  34  35  36  Average   18  17  55  60  18  16  25  33  29  37  28  58  33±17   male  female  female  male  female  male  female  female  male  female  male  male *No significant differences were found among the 3 treatment groups by ANOVA, or chi-square test. **Complete remission was obtained in 75% with CsA alone, 100% with CsA/PMT and 92% with PSL alone (p=0.0379). ***Mean time to complete remission was short in the CsA/PMT group and long in the CsA alone group (p=0.0018). Values were expressed as mean±SD.
response rate to our regimen with CsA alone suggests that remission of MCNS is possible with a lower dose and blood trough level than previously reported. In this regard, as our study population was limited to Japanese patients, our good results may suggest a specific racial predilection for CsA response. A previous CsA pharmacokinetic study documented that the bioavailability was significantly lower in black patients than Caucasian patients (9) .
Nonresponders to CsA alone were 3 patients with higher serum levels of cholesterol than those of responders. Ingulli et al reported that greater CsA dosages might be necessary to counteract the effect of hyperlipidemia to achieve the desired therapeutic trough blood levels (10). If we had escalated CsA dosages for the 3 patients, we might have obtained better results. Finally 2 of the 3 patients responded to LDL apheresis.
The rate and time for response in our PSL therapy group was better than those of other reports, as a recent Japanese group showed a favorable response in adult patients suffering from a first attack (1, 11, 12) . The difference in the response rate may be due to racial differences, or the relatively younger age of our patients might be responsible, since Korbet et al found that older patients had slower induction of CR (11) .
Prevention of relapse
CsA dependency is a major problem: relapse after tapering CsA dosage, or stopping CsA therapy. Previous reports documented that most patients with CsA relapsed after tapering or stopping CsA. Since there is no clinical way to predict relapse, we scheduled regimens of CsA with a longer term and with slower tapering of the dose in an attempt to prevent relapse (7) . In the CsA alone group, 7 of the 12 patients were relapsed during tapering or after withdrawal of CsA, but 5 patients were still in remission at the final observation. In the CsA/PMT group, relapses occurred in 3 of 12 patients with tapering of the dose of CsA. Maher et al reported successful remission-inducing effects of CsA alone (initial dose 7.7 mg/kg per day) in 10 patients with steroid-sensitive nephrotic syndrome, but all relapsed in a mean of 47.8 days after maintenance CsA therapy was discontinued after a mean of 115.3 days treatment (13) . Other reports on the induction of remission by CsA alone (5-10 mg/kg per day) for a short term resulted in similar remission and relapse rates (14, 15) . In this respect, our treatment regimens of CsA have the advantage of longer term remission with a lower incidence of relapse. Cumulative rates of sustained remission among the 3 groups were statistically similar.
The study is not randomized, but this is less important in MCNS than in most other glomerular diseases, as we have no accepted way to stratify for prognosis or likelihood of response to therapy.
Adverse effect
Low-dose CsA, despite long-term use was associated with fewer adverse reactions of CsA. Also, PMT related adverse reactions were not observed because fewer pulses were used in the present study. On the other hand, 3 patients treated with daily PSL alone experienced serious adverse reactions, and also many patients experienced cosmetic problems including moon face, acne, hirsutism, obesity, or hair loss. In contrast, the patients treated with CsA experienced fewer cosmetic problems. The cosmetic problem presented problems for some nephrotic patients in terms of their social life. We emphasized the factor of fewer cosmetic problems with low-dose CsA than with PSL alone.
At final observation, all patients with CsA had normal renal function and all patients but one had normal blood pressure. One major concern with the use of CsA has been its potential for inducing chronic nephrotoxicity. Generally nephrotoxicity due to CsA has been believed to correlate with higher dosage, increment serum creatinine and age (5) . In addition, nephrotoxicity is believed to be more severe in The frequency of medication-free subjects among the 3 treatment groups was the same by chi-square test.
focal-segmental glomerulosclerosis than MCNS and in steroid-resistant than in steroid-dependent nephrotic syndrome. Meyrier et al reported that tolerance up to 5.5 mg/kg per day of CsA was good in adult MCNS with normal renal function and no significant interstitial lesions (6) . Recent retrospective analysis has demonstrated that in autoimmune disease with normal renal function, the likelihood of development of nephrotoxicity could be minimized by using doses of about 5 mg/kg per day, and that the risk of nephrotoxicity is not affected by the length of CsA treatment, at least during the first year (5). These reports raised possibilities of the safety of long-term CsA monotherapy with a mean dose of 2.7 mg/kg per day. In contrast to those opinions, CsA nephrotoxicity is often undetectable by monitoring the serum creatinine or other laboratory parameters (16, 17) . Concerning this point, 5 of the 6 relapsing patients with long-term use of CsA had renal histology of no CsA toxities on repeat biopsy, although the present study for the evaluation of nephrotoxicity consists of deficits of the number undergoing repeat biopsy. At least nephrotoxicity did not develop after withdrawal. Therefore, we will perform repeat biopsy when patients are in sustained remission relapse in order to help determine therapeutic strategy. A recent interesting report suggests the recovery from CsA-associated arteriopathy but not from tubulointerstitial changes in childhood nephrotic syndrome (18) .
In conclusion, the CsA/PMT therapy is not only advantageous for rapid induction of CR but is also efficient for maintaining remission, with little evidence of CsA toxicity. Repeat renal biopsy may be warranted to allow an informed assessment of the risks and benefits of this therapy.
